View Item 

Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development

Access Status
Fulltext not available
Authors
Hua, Y.
Wang, I.
Liu, B.
Kelly, D.
Reid, Christopher
Liew, D.
Zhou, Y.
Wang, B.
Date
2017
Type
Journal Article

Metadata
Show full item record
Citation
Hua, Y. and Wang, I. and Liu, B. and Kelly, D. and Reid, C. and Liew, D. and Zhou, Y. et al. 2017. Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development. Future Cardiology. 13 (2): pp. 103-115.
Source Title
Future Cardiology
DOI
ISSN
School
Department of Health Policy and Management
URI
Collection
Abstract

© 2017 Future Medicine Ltd.Heart failure still has a significant disease burden with poor outcomes worldwide despite advances in therapy. The standard therapies have been focused on blockade of renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and mineralocorticoid antagonists and the sympathetic nervous system with ß-blockers. The natriuretic peptide system is a potential counter-regulatory system that promotes vasodilatation and natriuresis. Angiotensin receptor neprilysin inhibitors are a new class drug capable of blocking the renin-angiotensin-aldosterone system and enhancing the natriuretic peptide system to improve neurohormonal balance. The success of the PARADIGM-HF trial with LCZ696 and its approval for heart failure treatment is likely to generate a paradigm shift. This review summarises the current knowledge of LCZ696 with a focus on pharmacology, pharmacokinetics and pharmacodynamics, mechanisms of action, clinical efficacy and safety.